What Is HbA1c (Glycated Hemoglobin)? Normal vs Optimal Range Explained

The lab classifies HbA1c below 5.7% as "normal" and 5.7–6.4% as prediabetes, but cardiovascular and metabolic risk begins increasing well below the prediabetes threshold. An HbA1c of 5.5% corresponds to an average glucose of approximately 111 mg/dL—a level where glycation-mediated vascular damage is already measurable in epidemiological studies. The CTD documents over 9,800 compound interactions with hemoglobin glycation and glucose metabolism pathways, reflecting the massive number of pharmacological and dietary factors that influence long-term glucose control. The optimal range of 4.5–5.3% corresponds to an average glucose of approximately 82–105 mg/dL—the zone where glycation damage is minimized, cardiovascular risk is lowest, and cognitive function is optimally supported. Each 0.1% increase in HbA1c above 5.0% incrementally raises cardiovascular event risk.

PubMed indexes over 115,000 publications on HbA1c, making it one of the most studied biomarkers in clinical medicine. HbA1c captures something that fasting glucose and even fasting insulin cannot: the cumulative glucose exposure including post-meal spikes. A person with a normal fasting glucose of 85 mg/dL but dramatic post-meal spikes to 180 mg/dL will have an elevated HbA1c that reveals what fasting glucose misses. This is why HbA1c and fasting glucose can diverge—and when they do, HbA1c is usually the more clinically concerning number because it reflects the glucose exposure your blood vessels, nerves, and organs actually experienced over months. FAERS documents over 95,000 adverse event reports involving glucose dysregulation, with medication-induced HbA1c elevation being one of the most common metabolic complications.

HbA1c has important limitations that must be understood for accurate interpretation. Any condition that alters red blood cell lifespan changes the glycation window: hemolytic anemias, sickle cell disease, thalassemia, and chronic kidney disease can produce misleadingly low or high HbA1c results. Iron deficiency anemia extends red blood cell lifespan, producing falsely elevated HbA1c. Recent blood transfusion dilutes glycated hemoglobin with donor cells, temporarily lowering HbA1c. Hemoglobin variants (HbS, HbC, HbE) can interfere with certain HbA1c assay methods. When any of these conditions is present, fructosamine (which measures glycated albumin over 2–3 weeks) provides a more accurate intermediate-term glycemic assessment because it's independent of red blood cell biology.